C O M M U N I C A T I O N S
Table 1. Scope of the Rearrangement
Scheme 2
product a: R
)
)
CO2Et
SiMe3
entry
substrate
b: R
yieldc
Such structures are in wide use as haptens for antibody generation,
amino acid mimics, and as enzyme inhibitors.11
In summary, we have reported a unique [3,3]-rearrangement of
phosphonium ylides that provides access to phosphonates of
complex structure and wide ranging synthetic utility. Current
investigations are focused upon asymmetric variants of this reaction,
and results will be reported in due course.
Acknowledgment. A.K.M. is grateful for financial support from
the NIH (GM65330) and the Alfred P. Sloan Foundation. We thank
B. Chen for early technical assistance, and D. Trauner for
illuminating discussions.
Supporting Information Available: Experimental procedures and
characterization data for all new compounds. This material is available
References
(1) (a) Kolodiazhnyi, O. I. Phosphorus Ylides: Chemistry and Application
in Organic Synthesis; Wiley-VCH: New York, 1999. (b) Clark, J. S.
Nitrogen, Oxygen, and Sulfur Ylide Chemistry: A Practical Approach in
Chemistry; Oxford University Press: Oxford, 2002. (c) Johnson, W. A.
Ylides and Imines of Phosphorus; Wiley & Sons: New York, 1993.
(2) For example: (a) Shiraki, C.; Saito, H.; Takahashi, K.; Urakawa, C.; Hirata,
T. Synthesis 1988, 399-401. (b) Mikolajczyk, M.; Mikina, M.; Zurawinski,
R. Pure Appl. Chem. 1999, 71, 473-480. (c) Bernardi, L.; Zhuang, W.;
Jørgensen, K. A. J. Am. Chem. Soc. 2005, 127, 5772-5773.
(3) Baldwin, J. E.; Armstrong, C. H. J. Chem. Soc. D 1970, 11, 631b-632.
(4) Dimroth, K.; Schaffer, O.; Weiersha¨user, G. Chem. Ber. 1981, 114, 1752-
1766.
(5) Aggarwal, V. K.; Harvey, J. N.; Robiette, R. Angew. Chem., Int. Ed. 2005,
44, 2-5.
(6) For examples: (a) Aggarwal, V. K.; Fulton, J. R.; Sheldon, C. G.; de
Vincente, J. J. Am. Chem. Soc. 2003, 125, 6034-6035. (b) Lebel, H.;
Paquet, V.; Proulx, C. Angew. Chem., Int. Ed. 2001, 40, 2887-2890. (c)
Fujimura, O.; Honma, T. Tetrahedron Lett. 1998, 39, 625-626. (d) Lebel,
H.; Paquet, V. J. Am. Chem. Soc. 2004, 126, 320-328. (e) Mirafzal, G.
A.; Cheng, G. L.; Woo, L. K. J. Am. Chem. Soc. 2002, 124, 176-177. (f)
Lu, X. Y.; Fang, H.; Ni, Z. J. J. Organomet. Chem. 1989, 373, 77-84.
(g) Chen, Y.; Huang, L.; Ranade, M. A.; Zhang, X. P. J. Org. Chem.
2003, 68, 3714-3717.
a Conditions: (i) Allylic alcohol substrate (1 equiv), chlorophosphite (1
equiv), and Et3N (1 equiv), tol, 0 °C, 1 h. (ii) Ethyl diazoacetate (1.2 equiv),
1 mol % of ClFeTPP, 40 °C, 1 h f 110 °C, 7 h. b Conditions: (i) Allylic
alcohol substrate (1 equiv), chlorophosphite (1 equiv), and Et3N (1 equiv),
tol, 0 °C, 1 h. (ii) Trimethylsilyldiazoacetate (1.2 equiv), 1 mol % of
ClFeTPP, 40 °C, 1 h f 110 °C, 7 h. c Isolated yields.
(7) Under these conditions, no conversion to ylide is observed in the absence
of ClFeTPP catalyst.
particularly notable case as phosphonates such as 15a are excellent
intermediates for the butyrolactone-containing family of natural
products.10
(8) (a) Chen, B.; Mapp, A. K. J. Am. Chem. Soc. 2004, 126, 5364-5365. (b)
Chen, B.; Mapp, A. K. J. Am. Chem. Soc. 2005, 127, 6712-6718.
(9) (a) Aggarwal, V. K.; et al. J. Am. Chem. Soc. 2003, 125, 10926-10940.
(b) Furrow, M. E.; Myers, A. G. J. Am. Chem. Soc. 2004, 126, 12222-
12223. (c) Fulton, J. R.; Aggarwal, V. K.; de Vincente, J. Eur. J. Org.
Chem. 2005, 1479-1492.
The phosphonium ylide rearrangement affords entry into a range
of desirable synthetic targets (Scheme 2). For example, employment
of phosphonates such as 9a in a Horner-Wadsworth-Emmons
reaction produces nonsymmetrical, skipped dienes (16, for example)
in excellent yields and high stereoselectivity (see Supporting
Information for additional details). In addition, the phosphonates
are excellent substrates for conversion into R-aminophosphonic
esters via amination2c (17, for example). The tandem [3,3]-
rearrangement-amination sequence should thus provide ready
access to chiral, nonracemic aminophosphonic esters and acids.
(10) See: Minami, T.; Hirakawa, K.; Koyanagi, S.; Nakamura, S.; Yamaguchi,
M. J. Chem. Soc., Perkin Trans. 1 1990, 2385-2390.
(11) For examples: (a) Hirschmann, R.; Smith, A. B., III; Taylor, C. M.;
Benkovic, P. A.; Taylor, S. D.; Yager, K. M.; Sprengeler, P. A.; Benkovic,
S. J. Science 1994, 265, 234-237. (b) Stowasser, K.-H. B.; Jian-Qi, L.;
Peyman, A.; Ruppert, D. Tetrahedron Lett. 1992, 33, 6625-6628. (c)
Kafarski, P.; Lejczak, B. Curr. Med. Chem.: Anti-Cancer Agents 2001,
1, 301-312. (d) Patel, D. V.; Rielly-Gauvin, K.; Ryono, D. E.; Free, C.
A.; Rogers, W. L.; Smith, S. A.; DeForrest, J. M.; Oehl, R. S.; Petrillo,
E. W. J. Med. Chem. 1995, 38, 4557-4569.
JA058746Q
9
J. AM. CHEM. SOC. VOL. 128, NO. 14, 2006 4577